EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus
By selling off its critical care business, EUSA Pharma gets needed funds and freedom to fully focus on oncology and rare diseases, its CEO tells Scrip.
You may also be interested in...
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.